Weijuan Jia

1.3k total citations
34 papers, 1.0k citations indexed

About

Weijuan Jia is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Weijuan Jia has authored 34 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Cancer Research, 20 papers in Oncology and 14 papers in Pathology and Forensic Medicine. Recurrent topics in Weijuan Jia's work include Breast Cancer Treatment Studies (19 papers), Breast Lesions and Carcinomas (14 papers) and HER2/EGFR in Cancer Research (7 papers). Weijuan Jia is often cited by papers focused on Breast Cancer Treatment Studies (19 papers), Breast Lesions and Carcinomas (14 papers) and HER2/EGFR in Cancer Research (7 papers). Weijuan Jia collaborates with scholars based in China, United States and Hungary. Weijuan Jia's co-authors include Fengxi Su, Erwei Song, Shunrong Li, Kai Chen, Fengxi Su, Jiannan Wu, Heran Deng, Yaping Yang, Jieqiong Liu and Chang Gong and has published in prestigious journals such as Nature Communications, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Weijuan Jia

34 papers receiving 989 citations

Peers

Weijuan Jia

ONCOL

PFM

SURGE

Slim Ben Ahmed Tunisia

Kai Kammers United States

Ilary Ruscito Italy

Karen H. Lu United States

Hank Schmidt United States

Domenica Lovero Italy

Urvi Mujumdar United States

Synnöve Staff Finland

Blanca Cantos Spain

Frédéric Buxant Belgium

Slim Ben Ahmed Tunisia

Weijuan Jia

553 ×1.1

ONCOL

322 ×0.7

453 ×1.9

162 ×0.9

PFM

122 ×0.9

SURGE

Citations per year, relative to Weijuan Jia Weijuan Jia (= 1×) peers Slim Ben Ahmed

Countries citing papers authored by Weijuan Jia

Since Specialization

Citations

This map shows the geographic impact of Weijuan Jia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weijuan Jia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weijuan Jia more than expected).

Fields of papers citing papers by Weijuan Jia

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weijuan Jia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weijuan Jia. The network helps show where Weijuan Jia may publish in the future.

Co-authorship network of co-authors of Weijuan Jia

This figure shows the co-authorship network connecting the top 25 collaborators of Weijuan Jia. A scholar is included among the top collaborators of Weijuan Jia based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weijuan Jia. Weijuan Jia is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Jieqiong, Ying Wang, Zhenluan Tian, et al.. (2022). Multicenter phase II trial of Camrelizumab combined with Apatinib and Eribulin in heavily pretreated patients with advanced triple-negative breast cancer. Nature Communications. 13(1). 3011–3011. 67 indexed citations

Li, Qian, Yifan Wang, Weijuan Jia, et al.. (2019). Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade. Clinical Cancer Research. 26(7). 1712–1724. 116 indexed citations

Hu, Yue, Ran Gu, Jinghua Zhao, et al.. (2017). Prognostic significance of Ki67 in Chinese women diagnosed with ER+/HER2− breast cancers by the 2015 St. Gallen consensus classification. BMC Cancer. 17(1). 28–28. 7 indexed citations

Wang, Ying, Jieqiong Liu, Weijuan Jia, et al.. (2016). Comparison of the Therapeutic Efficacy of the Early and the Delayed Use of Vinorelbine-Based Regimens for Patients with Advanced Breast Cancer. Chemotherapy. 62(1). 71–79. 4 indexed citations

Zhao, Jinghua, Fengxi Su, Yue Hu, et al.. (2016). Prospective comparison of Sapylin and Avitene for reducing hydrops after axillary lymphadenectomy in breast cancer patients. Journal of Surgical Research. 210. 8–14. 1 indexed citations

Jia, Weijuan, Jiannan Wu, Haixia Jia, et al.. (2015). The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients. PLoS ONE. 10(11). e0143061–e0143061. 88 indexed citations

Wu, Jiannan, Shunrong Li, Weijuan Jia, et al.. (2015). Reduced Let-7a Is Associated with Chemoresistance in Primary Breast Cancer. PLoS ONE. 10(7). e0133643–e0133643. 34 indexed citations

Jia, Weijuan, et al.. (2014). HER2-enriched Tumors Have the Highest Risk of Local Recurrence in Chinese Patients Treated with Breast Conservation Therapy. Asian Pacific Journal of Cancer Prevention. 15(1). 315–320. 16 indexed citations

Jia, Haixia, Weijuan Jia, Yaping Yang, et al.. (2014). HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy. World Journal of Surgical Oncology. 12(1). 289–289. 20 indexed citations

10.

Zhao, Jianli, Jieqiong Liu, Kai Chen, et al.. (2014). What lies behind chemotherapy-induced amenorrhea for breast cancer patients: a meta-analysis. Breast Cancer Research and Treatment. 145(1). 113–128. 74 indexed citations

11.

Chen, Kai, Xiaolan Zhang, Heran Deng, et al.. (2014). Clinical Predictive Models for Chemotherapy-Induced Febrile Neutropenia in Breast Cancer Patients: A Validation Study. PLoS ONE. 9(6). e96413–e96413. 14 indexed citations

12.

Zhu, Liling, Liang Jin, Shunrong Li, et al.. (2013). Which nomogram is best for predicting non-sentinel lymph node metastasis in breast cancer patients? A meta-analysis. Breast Cancer Research and Treatment. 137(3). 783–795. 50 indexed citations

13.

Li, Shunrong, Jiannan Wu, Kai Chen, et al.. (2012). Clinical outcomes of 1,578 Chinese patients with breast benign diseases after ultrasound-guided vacuum-assisted excision: recurrence and the risk factors. The American Journal of Surgery. 205(1). 39–44. 16 indexed citations

14.

Liu, Jieqiong, Heran Deng, Weijuan Jia, et al.. (2012). Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment. Journal of Cancer Research and Clinical Oncology. 138(5). 837–842. 20 indexed citations

15.

Wu, Jiannan, Shunrong Li, Weijuan Jia, & Fengxi Su. (2011). Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer. Journal of Cancer Research and Clinical Oncology. 137(10). 1505–1510. 30 indexed citations

16.

Chen, Kai, Liling Zhu, Weijuan Jia, et al.. (2011). Validation and comparison of models to predict non‐sentinel lymph node metastasis in breast cancer patients. Cancer Science. 103(2). 274–281. 22 indexed citations

17.

Zhao, Ruihua, Jiannan Wu, Weijuan Jia, et al.. (2011). Plasma miR-221 as a Predictive Biomarker for Chemoresistance in Breast Cancer Patients who Previously Received Neoadjuvant Chemotherapy. Onkologie. 34(12). 675–680. 61 indexed citations

18.

Hu, Xiaoqu, Fengxi Su, Li Qin, et al.. (2006). Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo. Biochemical and Biophysical Research Communications. 346(3). 778–785. 15 indexed citations

19.

Su, Fengxi, Nengyong Ouyang, Pengcheng Zhu, et al.. (2005). Psychological stress induces chemoresistance in breast cancer by upregulating mdr1. Biochemical and Biophysical Research Communications. 329(3). 888–897. 61 indexed citations

20.

Su, Fengxi, Xiaoqu Hu, Weijuan Jia, et al.. (2003). Glutathion s transferase π indicates chemotherapy resistance in breast cancer. Journal of Surgical Research. 113(1). 102–108. 56 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact